Showing results (321-330 of 427) with videos related to
Sort By:
Pageof 43
JCO Oncology Practice|April 8, 2020
Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell DiseaseAlyssa A Schatz, Thomas K Oliver, Robert A Swarm, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II studyC Hudis, M Fornier, L Riccio, et al.Proceedings of the National Academy of Sciences of the United States of America|March 15, 2001
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trialT Gilewski, G Ragupathi, S Bhuta, et al.Cancer Prevention Research (Philadelphia, Pa.)|December 10, 2017
Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian WomenNeil M Iyengar, I-Chun Chen, Xi K Zhou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2016
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)Maura N Dickler, William T Barry, Constance T Cirrincione, et al.Journal of Clinical Pharmacology|December 6, 2019
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)Manish R Sharma, Shailly Mehrotra, Elizabeth Gray, et al.Breast Cancer Research and Treatment|March 12, 2017
Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)Gretchen G Kimmick, Brittny Major, Jonathan Clapp, et al.The New England Journal of Medicine|October 12, 2007
HER2 and response to paclitaxel in node-positive breast cancerDaniel F Hayes, Ann D Thor, Lynn G Dressler, et al.Proceedings of the National Academy of Sciences of the United States of America|February 16, 2011
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patientsMaurizio Scaltriti, Pieter J Eichhorn, Javier Cortés, et al.Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association|March 21, 2014
Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancerK D Crew, K A Ho, P Brown, et al.Pageof 43